Biotech Values

[DewDiligence]

I still own a small ADXS position, but I haven’t added during the sell-off following the 9/11/17 press release.

Inasmuch as my main reason for being long was/is the ADXS-NEO neoantigen-vaccine program partnered with AMGN, the delay in starting the phase-1 NEO trial (#msg-134670005) has lessened my enthusiasm for the stock.

Moreover, ADXS is running low on cash (#msg-134669697), so a financing transaction in the next few months is pretty likely, IMO, unless ADXS inks a new partnership deal.